SG11201900336YA - Radioligands for imaging the ido1 enzyme - Google Patents

Radioligands for imaging the ido1 enzyme

Info

Publication number
SG11201900336YA
SG11201900336YA SG11201900336YA SG11201900336YA SG11201900336YA SG 11201900336Y A SG11201900336Y A SG 11201900336YA SG 11201900336Y A SG11201900336Y A SG 11201900336YA SG 11201900336Y A SG11201900336Y A SG 11201900336YA SG 11201900336Y A SG11201900336Y A SG 11201900336YA
Authority
SG
Singapore
Prior art keywords
bristol
princeton
route
myers squibb
new jersey
Prior art date
Application number
SG11201900336YA
Inventor
David J Donnelly
Erin Lee Cole
Richard Charles Burrell
Wesley A Turley
Alban J Allentoff
Michael Arthur Wallace
James Aaron Balog
Audris Huang
Mette Skinbjerg
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201900336YA publication Critical patent/SG11201900336YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 IIIIIIIII101111101001111110101H11111110111110111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/017529 Al 25 January 2018 (25.01.2018) WI P0 I P C T (51) International Patent Classification: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, A61K 38/00 (2006.01) A61K 51/04 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: (84) Designated States (unless otherwise indicated, for every PCT/US2017/042510 kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 18 July 2017 (18.07.2017) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (25) Filing Language: English EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (30) Priority Data: KM, ML, MR, NE, SN, TD, TG). 62/364,020 19 July 2016 (19.07.2016) US Declarations under Rule 4.17: (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY — as to applicant's entitlement to apply for and be granted a [US/US]; Route 206 and Province Line Road, Princeton, patent (Rule 4.17(H)) New Jersey 08543 (US). — as to the applicant's entitlement to claim the priority of the (72) Inventors: DONNELLY, David J.; c/o Bristol-Myers earlier application (Rule 4.17(iii)) Squibb Company, Route 206 and Province Line Road, — of inventorship (Rule 4.17(iv)) Princeton, New Jersey 08543 (US). COLE, Erin Lee; c/o Published: — Bristol-Myers Squibb Company, Route 206 and Province — with international search report (Art. 21(3)) Line Road, Princeton, New Jersey 08543 (US). BURRELL, — Richard Charles; c/o Bristol-Myers Squibb Company, 5 = Research Parkway, Wallingford, Connecticut 06492 (US). = TURLEY, Wesley A.; c/o Bristol-Myers Squibb Compa- ny, 5 Research Parkway, Wallingford, Connecticut 06492 = (US). ALLENTOFF, Alban J.; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). WALLACE, Michael Arthur; c/ — o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). BALOG, James Aaron; c/o Bristol-Myers Squibb Company, Route = = 206 and Province Line Road, Princeton, New Jersey 08543 (US). HUANG, Audris; c/o Bristol-Myers Squibb Com- pany, Route 206 and Province Line Road, Princeton, New = Jersey 08543 (US). SKINBJERG, Mette; c/o Bristol-My- ers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). = Agent: FARQUHARSON-TORRES, Serena et al.; Bris- tol-Myers Squibb Company, Route 206 and Province Line (74) = Road, Princeton, New Jersey 08543 (US). Designated States (unless otherwise indicated, for every (81) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = _ 1-1 01 ei kin IN 1-1 © —.... 00 1-1 (54) Title: RADIOLIGANDS FOR IMAGING THE IDO1 ENZYME © ei (57) : The present invention relates to radiolabeled IDO1 inhibitors or pharmaceutically acceptable salts thereof which are 0 useful for the quantitative imaging of IDO enzymes in mammals.
SG11201900336YA 2016-07-19 2017-07-18 Radioligands for imaging the ido1 enzyme SG11201900336YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364020P 2016-07-19 2016-07-19
PCT/US2017/042510 WO2018017529A1 (en) 2016-07-19 2017-07-18 Radioligands for imaging the ido1 enzyme

Publications (1)

Publication Number Publication Date
SG11201900336YA true SG11201900336YA (en) 2019-02-27

Family

ID=59416832

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900336YA SG11201900336YA (en) 2016-07-19 2017-07-18 Radioligands for imaging the ido1 enzyme

Country Status (13)

Country Link
US (2) US20190282714A1 (en)
EP (1) EP3487516A1 (en)
JP (1) JP6987840B2 (en)
KR (1) KR102513886B1 (en)
CN (1) CN109475594A (en)
AU (1) AU2017298262A1 (en)
BR (1) BR112019000499A2 (en)
CA (1) CA3031079A1 (en)
EA (1) EA039877B1 (en)
IL (1) IL264187B (en)
MX (1) MX2019000508A (en)
SG (1) SG11201900336YA (en)
WO (1) WO2018017529A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528300A (en) * 2016-08-26 2019-10-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Indoleamine 2,3-dioxygenase inhibitors and methods of use thereof
US11236048B2 (en) * 2017-06-30 2022-02-01 Bristol-Myers Squibb Company Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation
AU2017440613A1 (en) 2017-11-21 2020-07-09 Guangdong Oppo Mobile Telecommunications Corp., Ltd. Information transmission method, network device, and terminal device
CN111417626A (en) * 2017-12-05 2020-07-14 葛兰素史克知识产权开发有限公司 Modulators of indoleamine2,3-dioxygenase
CN110357813A (en) * 2018-04-09 2019-10-22 信达生物制药(苏州)有限公司 A kind of new indole amine 2,3- dioxygenase inhibitor and its preparation method and application
AR120935A1 (en) * 2020-01-02 2022-03-30 Hutchison Medipharma Ltd AMIDE DERIVATIVES AND USES THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182359A (en) * 2007-11-09 2008-05-21 中山大学 Human indoleamine 2,3-dioxygenase polyclonal antibody as well as preparation method and uses thereof
MX360640B (en) * 2010-03-01 2018-11-09 Tau Therapeutics Llc Star Cancer diagnosis and imaging.
WO2016040458A2 (en) * 2014-09-09 2016-03-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pet probes of radiofluorinated carboximidamides for ido-targeted imaging
UY36390A (en) * 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
US20190282714A1 (en) 2019-09-19
JP6987840B2 (en) 2022-01-05
KR20190030727A (en) 2019-03-22
IL264187B (en) 2021-06-30
CA3031079A1 (en) 2018-01-25
MX2019000508A (en) 2019-03-28
EA039877B1 (en) 2022-03-23
WO2018017529A1 (en) 2018-01-25
IL264187A (en) 2019-02-28
BR112019000499A2 (en) 2019-04-24
EP3487516A1 (en) 2019-05-29
EA201990198A1 (en) 2019-06-28
CN109475594A (en) 2019-03-15
US20220305144A1 (en) 2022-09-29
AU2017298262A1 (en) 2019-03-07
JP2019527225A (en) 2019-09-26
KR102513886B1 (en) 2023-03-27

Similar Documents

Publication Publication Date Title
SG11201900336YA (en) Radioligands for imaging the ido1 enzyme
SG11201804934PA (en) Novel Compounds
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201900844UA (en) Amino pyrimidine ssao inhibitors
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201909011PA (en) Niraparib compositions
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201803816RA (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease
SG11201809793UA (en) Tl1a antibodies and uses thereof
SG11201803692PA (en) Anti-5t4 antibodies and antibody-drug conjugates
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201900043TA (en) Antibody formulations
SG11202000077RA (en) Methods of treating behavior alterations
SG11201907217RA (en) Pharmaceutical combinations for treating cancer